NEW YORK (GenomeWeb News) – Luminex has closed its public offering of 4,025,000 shares of common stock, including the over-allotment option of 525,000 shares, raising roughly $74.3 million in net proceeds.
 
The offering was priced at $19.91 per share, which was Luminex’s closing price on June 24. In late Monday afternoon trade, the firm’s shares were down .5 percent at $20.68.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.